ArticleEuropean radiology2026
Outcomes of percutaneous metallic stenting for malignant bilioenterostomy stricture: a retrospective single-center study of 368 patients.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the technical and clinical outcomes of percutaneous metallic stenting in patients with malignant bilioenterostomy obstruction and to identify risk factors affecting stent patency. MATERIALS AND
methodsThis retrospective study included 368 patients (240 men, 128 women; mean age, 68.2 years; range, 39-95 years) who underwent percutaneous biliary metallic stent placement between March 2012 and November 2023. Patients were categorized into three groups based on stent type: covered, single uncovered, and double uncovered.
resultsTechnical success was achieved in all patients. Uncovered stents-single uncovered (n = 208; 56.5%) and double uncovered (n = 50; 13.6%)-were placed in 70.1% of patients, while covered stents were used in 29.9%. Major and minor complication rates were 1.1% and 1.9%. Successful internal drainage, defined as removal of the temporary drainage catheter, was achieved in 87.8% of patients. Median survival and stent patency times were 241 days (95% CI, 216-266) and 255 days (95% CI, 194.7-315.3). No significant factors were associated with overall survival. Stent occlusion occurred in 50.5% of patients, most commonly due to tumor ingrowth (74.3%). On multivariate Cox regression, double uncovered stent placement (HR, 0.440; 95% CI, 0.295-0.656; p < 0.001), covered stent placement (HR, 0.301; 95% CI, 0.161-0.564; p < 0.001), and post-stenting serum bilirubin < 2.0 mg/dL (HR, 0.715; 95% CI, 0.517-0.990; p = 0.043) were independent predictors of prolonged stent patency.
conclusionPercutaneous metallic stenting is a safe and effective treatment for malignant bilioenterostomy obstruction. Covered and double-uncovered stents are associated with longer stent patency. KEY POINTS: Question: What are the technical and clinical outcomes of percutaneous metallic stenting in malignant bilioenterostomy obstruction, and which factors affect stent patency?
findingsCovered and double-uncovered stents showed significantly longer patency. Stent type and bilirubin < 2.0 mg/dL were independent predictors of patency. CLINICAL RELEVANCE: Percutaneous metallic stenting is safe and effective for malignant bilioenterostomy obstruction. Covered and double uncovered stents prolong patency, supporting their use as preferred options to improve long-term biliary drainage and patient outcomes.
Indexed as
Identifiers
41826765What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.